Fig 4. Cumulative survival rates of patients with the initial IPF diagnosis.

The 5-year survival rate was 81.5% in the MPO-ANCA-positive patients, including patients who subsequently developed MPA, and 45.4% in the MPO-ANCA-negative patients. P = 0.01 by log-rank test. IPF, idiopathic pulmonary fibrosis; MPO-ANCA, myeloperoxidase-anti-neutrophil cytoplasmic antibody; MPA, microscopic polyangiitis.